Midazolam as a Medical Countermeasure for Organophosphorus (OP) Compound Exposure

The contract seeks proposals for the development and utilization of Midazolam as a medical countermeasure to treat exposure to organophosphorus compounds, which are highly toxic chemicals often associated with nerve agents and pesticides. This solicitation, identified as RFP-13-100-SOL-00002, was posted on January 30, 2013, and falls under the NAICS code 325412, which pertains to pharmaceutical preparation manufacturing. The focus is on advancing medical research and readiness in response to potential chemical threats by leveraging Midazolam's pharmacological properties. Key personnel involved in managing the contract include Contract Specialist Susan Cortes-Shrank and Contracting Officer Jason Bell, both accessible via their provided contact information at the Department of Health and Human Services. While the solicitation details do not specify the organization type, set-aside status, or exact locations for performance, they emphasize the federal government's commitment to enhancing public health defense capabilities through pharmaceutical innovation and preparedness. Amendment 2 has been posted, indicating ongoing updates and refinements to the contract’s requirements or scope.